Allulose Concerns: Tolerance, Symptoms, and Safety

Gastrointestinal reactions should be considered based on actual exposure

Most of allulose is absorbed in the small intestine and excreted as a complete molecule in the urine, while a small amount of unabsorbed portion enters the large intestine. The latter increases the osmotic load and water content in the intestinal lumen and may be accompanied by limited fermentation and gas production, so loose stools, diarrhea, abdominal distension, flatulence or abdominal pain may occur when intake is high. This mechanism may explain some gastrointestinal reactions, but the symptoms themselves cannot be considered evidence of allergies, poisoning, or intestinal damage.

Human tolerance studies suggest that the response varies with dose and individual. In a trial of 30 healthy young adults, 44.83% reported diarrhea and 13.79% reported severe diarrhea when a single intake of 0.5 g/kg was taken; the study’s proposed single intake of 0.4 g/kg and full-day intake of 0.9 g/kg can only be understood under the conditions of this trial. Another study of 49 healthy Chinese adults compared 24 g and 36 g daily for 30 days. 48% reported gastrointestinal symptoms at least once, most of which occurred within the first few days and were mild and short-lived. The proportions of participants with diarrhea and abdominal distension were 24% and 28%, respectively. These study doses cannot be directly rewritten as fixed upper limits for everyone.

Product formulation can alter symptom attribution

When evaluating products containing allulose, the actual content per serving and the cumulative intake throughout the day are the basis, and conditions such as single concentrated or divided intake, fasting or with meals, as well as powders, syrups and other food bases should also be considered. For compounded products, other ingredients such as erythritol and dietary fiber should be considered separately, because the same product name cannot eliminate these exposure differences.

Symptoms after ingestion, such as headache, nausea, and skin changes, cannot alone prove an allulose allergy. In a study of healthy adults who received 24 or 36 g daily for 30 days, 16% reported at least one headache and 14% reported at least one nausea; there was no significant difference in the proportion of corresponding symptoms between the two groups, and the study did not have a placebo group without D-allulose, so it cannot be determined that allulose caused these symptoms.

The complete formulation also affects the judgment of sensitive reactions. The risk assessment of a particular D-allulose new food application concluded that the enzyme produced could be a potential source of protein in the final product; however, due to a lack of sufficient evidence to prove that the final product does not contain protein, the sensitization potential of the applied product could not be determined. This only indicates that there is a data gap in this particular application, and it cannot be inferred that D-allulose molecules are necessarily sensitized, nor can it be inferred that other products are necessarily free of sensitization risk.

Special populations and long-term evidence need to be counted separately

The available data are insufficient to establish a conclusion that the safe dose, recommended dose, or risk is zero for pregnant or breastfeeding individuals. The aforementioned 24 g or 36 g daily, 30-day healthy adult trial excluded pregnant and breastfeeding participants, and the results cannot be directly extrapolated; the existing data are also insufficient to determine whether allulose enters human milk, the concentration in breast milk, the exposure level in infants, and its effect on lactation or infants.

Compared to sucrose, allulose may reduce the energy and acute glycemic load of the ingredients themselves, but the energy or sugar load of the finished product may only decrease accordingly when sucrose is actually replaced and is not compensated by other ingredients or additional intake. Changes in postprandial blood glucose or insulin within a specific meal and time window cannot directly lead to long-term disease prevention, overall metabolic improvement, or therapeutic effects. The existing evidence does not establish a uniform recommended dosage or daily upper limit applicable to everyone, nor can any study dosage be changed to a general dosage statement for Saigao products.

Therefore, when judging the actual product, one should return to the actual intake per serving and throughout the day, the complete formula, and the specific symptom situation. Persistent, severe, or accompanied by other abnormal gastrointestinal symptoms, headache, nausea, or skin reactions cannot be attributed solely to allulose and should be evaluated independently clinically.